Huay Cheem Tan
Voorzitter bij Singapore Heart Foundation
Profiel
Huay Cheem Tan is currently the Chairman of the Singapore Heart Foundation and a Professor at the Yong Loo Lin School of Medicine.
He previously served as an Independent Non-Executive Director at HeMo (China) Bioengineering Co., Ltd.
and held the position of President at the Singapore Cardiac Society from 2003 to 2005 and the Asian Pacific Society of Interventional Cardiology from 2014 to 2019.
Tan received his graduate degree from the National University of Singapore in 1992.
Actieve functies van Huay Cheem Tan
| Bedrijven | Functie | Begin |
|---|---|---|
| Yong Loo Lin School of Medicine | Corporate Officer/Principal | - |
| Singapore Heart Foundation | Voorzitter | - |
Eerdere bekende functies van Huay Cheem Tan
| Bedrijven | Functie | Einde |
|---|---|---|
| Asian Pacific Society of Interventional Cardiology | President | 01-01-2019 |
| Singapore Cardiac Society | President | 01-01-2005 |
HeMo (China) Bioengineering Co., Ltd.
 HeMo (China) Bioengineering Co., Ltd. Information Technology ServicesTechnology Services HeMo Bioengineering Ltd. operates as a medical device company. Its portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. The company was founded in June 21, 2017 and is headquartered in Weihai, China. | Directeur/Bestuurslid | - |
Opleiding van Huay Cheem Tan
| National University of Singapore | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
| Singapore Heart Foundation | |
| Singapore Cardiac Society | |
HeMo (China) Bioengineering Co., Ltd.
HeMo (China) Bioengineering Co., Ltd. Information Technology ServicesTechnology Services HeMo Bioengineering Ltd. operates as a medical device company. Its portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. The company was founded in June 21, 2017 and is headquartered in Weihai, China. | Technology Services |
| Asian Pacific Society of Interventional Cardiology |
